Alpha Therapy Data Reset Prostate Cancer's Playbook

Early AcTION trial results show actinium-225 PSMA-617 driving deeper responses than beta-emitting rivals.

4 Jun 2026

New results from the AcTION trial, presented at the American Society of Clinical Oncology's annual meeting, offer the first prospective look at actinium-225 labeled PSMA-617 in men with metastatic castration resistant prostate cancer. The alpha emitting radioligand is being tested as a successor to the beta emitting lutetium-177 PSMA-617 therapies already on the market.

The numbers are striking for treatment naive patients. Among men who had not yet received chemotherapy, an androgen receptor pathway inhibitor or lutetium-177 PSMA therapy, the PSA50 response rate hit 100 percent, with a PSA90 rate of 90.9 percent. Patients who had already been through lutetium-177 PSMA treatment saw a more modest PSA50 rate of 56.3 percent, a gap that underscores how much prior therapy shapes outcomes.

Jeremie Calais of the University of California, Los Angeles, who presented the discussant analysis, explained the mechanism behind the divergence. Alpha particles deliver radiation roughly a hundred times more densely ionizing than beta particles, meaning far fewer hits are needed to kill a cancer cell. That radiobiological edge may explain the deeper responses, though it brings distinct toxicity considerations that demand close monitoring.

Xerostomia, a persistent dryness of the mouth tied to salivary gland exposure, remains a common side effect across actinium-225 PSMA studies. Researchers say existing toxicity grading tools still fail to capture its true clinical burden on patients.

More than a dozen additional actinium-225 PSMA trials are now underway, spanning everything from oligometastatic hormone sensitive disease to advanced metastatic castration resistant cancer. Parallel programs are testing copper-67, terbium-161 and lead-212 as alternative radionuclide platforms, suggesting the field is far from settling on a single isotope of choice.